[Her2 positive breast cancer: practices].


The molecular classification of Perou and Sørlie breast tumors has to streamline, systematize and make effective use of targeted therapies against specific molecular subtypes, including breast HER2 positive. Trastuzumab and lapatinib are currently the two therapies targeting HER2, which have demonstrated their effectiveness in clinical practice. This… (More)


Cite this paper

@article{Campone2011Her2PB, title={[Her2 positive breast cancer: practices].}, author={Mario Campone and Dominique Berton-Rigaud and Emmanuelle Bourbouloux and Sadot Sophie and Alain Zanetti and Jean-S{\'e}bastien Fr{\'e}nel}, journal={Bulletin du cancer}, year={2011}, volume={98 2}, pages={154-63} }